{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-001063","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.912484+00:00","generated_at":"2026-05-16T11:34:37.961731+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Positive Phase 1b asthma data for zumilokibart; FeNO reduction 60%, durable to 32 weeks; 2026 milestones","bullets":["Zumilokibart showed maximum mean FeNO reduction of 45 ppb (60% decrease) after single 720 mg dose; suppression durable through 16 weeks in all patients and up to 32 weeks in some.","Favorable safety profile: no Grade ≥3 TEAEs, SAEs, conjunctivitis, injection site reactions, or anti-drug antibodies; TEAEs included GERD and upper respiratory infection.","Positive trends in FEV1 and Type 2 biomarkers; further data to be presented at medical conferences.","2026 milestones: APEX Part A (AD, 52-week) data Q1; Part B (16-week) data Q2 (347 patients enrolled); Phase 3 AD start 2H 2026; APG279 vs DUPIXENT readout 2H 2026 (80 patients).","Pro forma cash $913M as of Sept 30, 2025; cash runway into 2H 2028 supports advancement to potential 2029 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-001063","json":"https://secwatch.observer/filing/0001104659-26-001063.json","markdown":"https://secwatch.observer/filing/0001104659-26-001063.md","text":"https://secwatch.observer/filing/0001104659-26-001063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926001063/0001104659-26-001063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926001063/tm261950d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:34:37.961731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}